Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Delayed Quote. Delayed  - 10/19 04:29:16 pm
239.4 CHF   -2.01%
02:19pDJEuropean Corporate Roundup for Thursday
11:31aDJEuropean Corporate Roundup for Thursday
10:14a ROCHE : Swiss biotech group Roche sees 5 pct rise in 9-month sales
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
04:27pRoche Holding given CHF 260 PT by UBS AG. neutral rating.  
01:47pRoche Holding ADR reports Q3 results  
01:42p$RHHBY: Roche Hldg reports Q3 sales and reaffirms FY17 sales outlook  
01:23pRoche Q3 top line up 5%, guidance confirmed  
11:53aNew MS drug #Ocrevus lifts #Roche as #biosimilars bite, with #Rituxan/MabTher..
2
11:24aUPDATE 2-New MS drug lifts Roche as biosimilars bite in Europe  
10:53aSwiss biotech group Roche sees 5 pct rise in 9-month sales - Washington Post .. 
09:53aSame old, same old at #Roche. Since the Novo Nordisk romp my current fav Eur.. 
08:24aUPDATE 1-Roche Q3 sales beat forecasts as Ocrevus shines  
08:10aRoche third-quarter sales beat forecasts as Ocrevus shines
2
07:39aRoche Q3 sales beat forecasts as Ocrevus shines  
07:29aUS helps offset lower European sales for Roche  
07:28aUS helps offset lower European sales for Roche  
07:27aUS helps offset lower European sales for Roche  
07:27aUS helps offset lower European sales for Roche
6
10/18Senseonics Holdings Inc $SENS Shares Down 8.8%  
10/18Roche Holding Ltd. $RHHBY Downgraded by Citigroup Inc. to Neutral  
10/18Roche Holding downgraded by Citigroup Inc. to neutral.  
10/18I am certainly concerned about price caps: Shravan Subramanyam, MD of Roche D.. 
10/18Steven J. Kafka Sells 3,361 Shares of Foundation Medicine, Inc. $FMI Stock  
10/18Roche Holding given CHF 255 PT by Citigroup Inc.. neutral rating.  
10/18Roche Holding given CHF 325 PT by Goldman Sachs Group, Inc. (The). buy rating.. 
10/17$FMI - Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Foundati.. 
10/17Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMoti.. 
10/17Steven J. Kafka Sells 3,361 Shares of Foundation Medicine, Inc. $FMI Stock  
10/16Senseonics Holdings, Inc. Schedules Third Quarter 2017 Earnings Release and C.. 
10/16#2 today Roche ties a $387M knot with Warp Drive Bio in collaboration spotlig..
5
10/16Big #pharma firm Roche, will pay up to $87 million for access to novel natura..
7
10/16Roche ties a $387M knot with Warp Drive Bio in collaboration spotlighting new.. 
10/16Roche Holding's buy rating reiterated at J P Morgan Chase & Co.  
10/16Luxor Announces Paul Roche as President  
10/16Roche Holding given CHF 295 PT by Jefferies Group LLC. buy rating.  
10/16$FMI (+0.0% pre) Foundation Medicine to Present Validation for FoundationOne ..
1
10/16#ovariancancer Foundation Medicine to Present Validation for FoundationOne CD..
1
10/16Foundation Medicine to Present Validation for FoundationOne CDx™, a Comprehen.. 
10/16Foundation Medicine to Present Validation for FoundationOne CDx™, a Comprehen.. 
10/16Roche ties a $387M knot with Warp Drive in collaboration spotlighting new cla.. 
10/16Roche links with Warp Drive Bio in antibiotics deal  
10/16Roche ties a $387M knot with Warp Drive Bio in collaboration spotlighting new..
12
10/16Roche’s Alecensa wins EU panel’s nod against mutated lung cancer | Pharma Mag.. 
10/16Roche taps Warp Drive to discover novel antibiotic classes in $387M pact
2
10/16Roche taps Warp Drive to discover novel antibiotic classes in $387M pact:
11
10/16Roche Holding given CHF 260 PT by Credit Suisse Group. neutral rating.  
10/15'Double whammy' for Roche as manufacturing patent losses loom: Reuters  
10/14Belleville board OKs plans for former Roche site  
10/14Roche's Alecensa wins EU panel's nod against mutated lung cancer  
10/13With Roche's loss of 'Cabilly patents' more than $600M in royalties dissipate..
2
10/13Roche's Alecensa wins EU panel's nod against mutated lung cancer  
10/13No sale for Novartis' $14B Roche stake, but the revamp's not done
1
10/13Roche Ireland runs up further losses following €130m writedown
1
More tweets
Qtime:219
Financials ( CHF)
Sales 2017 53 455 M
EBIT 2017 18 264 M
Net income 2017 11 176 M
Debt 2017 9 903 M
Yield 2017 3,52%
P/E ratio 2017 18,16
P/E ratio 2018 16,53
EV / Sales 2017 4,14x
EV / Sales 2018 3,90x
Capitalization 212 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 274  CHF
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.5.55%215 760
JOHNSON & JOHNSON22.11%377 585
NOVARTIS13.50%226 453
PFIZER10.31%213 372
MERCK AND COMPANY7.88%173 214
AMGEN27.41%135 924